Prevention of neurologic disability associated with preterm birth is one of the major
challenges in current perinatal medicine. Magnesium sulfate (MgSO4), the focus of this …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Magnesium sulfate in some dosage given before very preterm pregnancy delivery is
beneficial for fetal neuroprotection. The exact dose, duration, and timing of administration to …

In women at risk of early preterm imminent birth, from viability to 30 weeks of gestation, use
of MgSO4 for neuroprotection of the fetus is recommended. In pregnancies below 32–34 …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

There is an important unmet need to improve long term outcomes of encephalopathy for
preterm and term infants. Meta-analyses of large controlled trials suggest that maternal …

Background Magnesium sulfate is an accepted intervention for fetal neuroprotection. There
are some perceived differences in the international recommendations on the use …

Objective To evaluate whether magnesium sulphate (MgSO4) given to women at risk of very‐
preterm birth would be neuroprotective in preterm newborns and would prevent neonatal …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …